EGLN1:宫颈癌预后不良的生物标志物和治疗目标。

IF 1.1 4区 生物学 Q4 GENETICS & HEREDITY
Yi-Ting Zhang, Lin-Jing Xu, Ling Li
{"title":"EGLN1:宫颈癌预后不良的生物标志物和治疗目标。","authors":"Yi-Ting Zhang, Lin-Jing Xu, Ling Li","doi":"10.1089/gtmb.2023.0024","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> To conduct bioinformatics analysis on the prognostic effect, mechanism of action, and drug sensitivity of Egl-9 family hypoxia-inducible factor 1 (<i>EGLN1</i>) expression on cervical cancer. <b><i>Methods:</i></b> Bioinformatics were obtained from Gene Expression Profiling Interactive Analysis (GEPIA), Tumor Immune Estimation Resource (TIMER), and the human cancer metastasis database (HCMDB), and the effect of <i>EGLN1</i> expression level on the prognosis of cervical cancer was comprehensively analyzed. The protein-protein interaction network was constructed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and the possible mechanism of <i>EGLN1</i> affecting the prognosis of cervical cancer was discussed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. In addition, Gene Set Cancer Analysis (GSCALite) was used to predict sensitive drugs online. <b><i>Results:</i></b> The higher the expression level of <i>EGLN1</i>, the shorter the tumor-free survival time and overall survival time of cervical cancer. The higher the stage of cervical cancer, the higher the expression level of <i>EGLN1</i>. The expression of <i>EGLN1</i> affects the degree of immune infiltration, the variation of somatic copy number, and the level of N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification in cervical cancer. COX regression model suggested that <i>EGLN1</i> was an independent prognostic factor of cervical cancer. <b><i>Conclusions:</i></b> The high expression of <i>EGLN1</i> in cervical cancer is an independent risk factor for the prognosis of cervical cancer, which affects the prognosis of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) through different signal pathways. It is expected to be used to predict the sensitive anticancer drugs for the treatment of cervical cancer.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<i>EGLN1:</i> A Biomarker of Poor Prognosis of Cervical Cancer and a Target of Treatment.\",\"authors\":\"Yi-Ting Zhang, Lin-Jing Xu, Ling Li\",\"doi\":\"10.1089/gtmb.2023.0024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Objective:</i></b> To conduct bioinformatics analysis on the prognostic effect, mechanism of action, and drug sensitivity of Egl-9 family hypoxia-inducible factor 1 (<i>EGLN1</i>) expression on cervical cancer. <b><i>Methods:</i></b> Bioinformatics were obtained from Gene Expression Profiling Interactive Analysis (GEPIA), Tumor Immune Estimation Resource (TIMER), and the human cancer metastasis database (HCMDB), and the effect of <i>EGLN1</i> expression level on the prognosis of cervical cancer was comprehensively analyzed. The protein-protein interaction network was constructed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and the possible mechanism of <i>EGLN1</i> affecting the prognosis of cervical cancer was discussed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. In addition, Gene Set Cancer Analysis (GSCALite) was used to predict sensitive drugs online. <b><i>Results:</i></b> The higher the expression level of <i>EGLN1</i>, the shorter the tumor-free survival time and overall survival time of cervical cancer. The higher the stage of cervical cancer, the higher the expression level of <i>EGLN1</i>. The expression of <i>EGLN1</i> affects the degree of immune infiltration, the variation of somatic copy number, and the level of N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification in cervical cancer. COX regression model suggested that <i>EGLN1</i> was an independent prognostic factor of cervical cancer. <b><i>Conclusions:</i></b> The high expression of <i>EGLN1</i> in cervical cancer is an independent risk factor for the prognosis of cervical cancer, which affects the prognosis of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) through different signal pathways. It is expected to be used to predict the sensitive anticancer drugs for the treatment of cervical cancer.</p>\",\"PeriodicalId\":12603,\"journal\":{\"name\":\"Genetic testing and molecular biomarkers\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Genetic testing and molecular biomarkers\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1089/gtmb.2023.0024\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2023.0024","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

目的对Egl-9家族缺氧诱导因子1(EGLN1)表达对宫颈癌的预后影响、作用机制和药物敏感性进行生物信息学分析。研究方法从基因表达谱交互分析(GEPIA)、肿瘤免疫估算资源(TIMER)和人类癌症转移数据库(HCMDB)中获取生物信息,综合分析EGLN1表达水平对宫颈癌预后的影响。利用检索基因/蛋白相互作用的搜索工具(STRING)构建了蛋白-蛋白相互作用网络,并通过基因本体(GO)和京都基因组百科全书(KEGG)分析探讨了EGLN1影响宫颈癌预后的可能机制。此外,还利用基因组癌症分析(GSCALite)在线预测敏感药物。结果显示EGLN1表达水平越高,宫颈癌的无瘤生存时间和总生存时间越短。宫颈癌分期越高,EGLN1的表达水平越高。EGLN1的表达会影响宫颈癌的免疫浸润程度、体细胞拷贝数的变化以及N6-甲基腺苷(m6A)的修饰水平。COX回归模型表明,EGLN1是宫颈癌的一个独立预后因素。结论EGLN1在宫颈癌中的高表达是宫颈癌预后的独立危险因素,它通过不同的信号通路影响宫颈鳞癌和宫颈内膜腺癌(CESC)的预后。它有望用于预测治疗宫颈癌的敏感抗癌药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
EGLN1: A Biomarker of Poor Prognosis of Cervical Cancer and a Target of Treatment.

Objective: To conduct bioinformatics analysis on the prognostic effect, mechanism of action, and drug sensitivity of Egl-9 family hypoxia-inducible factor 1 (EGLN1) expression on cervical cancer. Methods: Bioinformatics were obtained from Gene Expression Profiling Interactive Analysis (GEPIA), Tumor Immune Estimation Resource (TIMER), and the human cancer metastasis database (HCMDB), and the effect of EGLN1 expression level on the prognosis of cervical cancer was comprehensively analyzed. The protein-protein interaction network was constructed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), and the possible mechanism of EGLN1 affecting the prognosis of cervical cancer was discussed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. In addition, Gene Set Cancer Analysis (GSCALite) was used to predict sensitive drugs online. Results: The higher the expression level of EGLN1, the shorter the tumor-free survival time and overall survival time of cervical cancer. The higher the stage of cervical cancer, the higher the expression level of EGLN1. The expression of EGLN1 affects the degree of immune infiltration, the variation of somatic copy number, and the level of N6-methyladenosine (m6A) modification in cervical cancer. COX regression model suggested that EGLN1 was an independent prognostic factor of cervical cancer. Conclusions: The high expression of EGLN1 in cervical cancer is an independent risk factor for the prognosis of cervical cancer, which affects the prognosis of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) through different signal pathways. It is expected to be used to predict the sensitive anticancer drugs for the treatment of cervical cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.50
自引率
7.10%
发文量
63
审稿时长
1 months
期刊介绍: Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results. Genetic Testing and Molecular Biomarkers coverage includes: -Diagnosis across the life span- Risk assessment- Carrier detection in individuals, couples, and populations- Novel methods and new instrumentation for genetic testing- Results of molecular, biochemical, and cytogenetic testing- Genetic counseling
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信